ALP Bio Raises $2.1M for AI Immune Organoid Platform

Jan de Vries · 2026-04-30

A Swiss biotech startup just made a move that could change how drug developers tackle a massive hidden cost in biologics. ALP Bio AG, based in Schlieren, has raised $2.1 million in pre-Seed funding to push forward its platform that blends human immune organoid biology with generative AI. This is about catching immunogenicity risks early. You know, those immune responses that can wreck a promising drug in late-stage trials. The round was led by Munich-based VC 42CAP, with support from Venture Kick and a group of strategic angel investors. ### Why Immunogenicity Matters So Much Immunogenicity is basically your body's immune system reacting to a therapeutic drug as if it's a threat. For biologics, this is a huge problem. It can reduce how well a drug works, create safety issues, or force teams to scrap years of work. Right now, most of these problems only show up in clinical trials. By then, companies have already poured millions into development. Dr. Christian Vahlensieck, CEO of ALP Bio, puts it bluntly: "Immunogenicity is one of the largest hidden costs in biologics, and the industry has accepted late-stage surprises as the norm for too long." ### What ALP Bio's Platform Actually Does The company is building a hybrid platform. On one side, they use human immune organoids. These are lab-grown mini versions of immune tissues, like tonsil tissue, that mimic real immune activity. On the other side, they layer in machine learning models. Together, these tools help antibody developers predict and reduce anti-drug antibody risk earlier in discovery. Instead of waiting for clinical trial failures, teams can get actionable feedback during the design phase. Dr. Lucas Schaus, CSO, adds: "By combining human immune organoid readouts with AI, we can generate the type of biological feedback needed to make antibody design more informed, iterative, and ultimately more useful." ### The Bigger Funding Picture in Europe ALP Bio's raise fits into a broader 2026 funding pattern across Europe. We're seeing serious money flow into AI-enabled drug discovery, human-relevant preclinical biology, and biologics infrastructure. Take Zurich-based Rivia, which pulled in $14.7 million Series A for clinical trial data infrastructure. Or Geneva's FluoSphera, which raised $1.4 million for human-relevant drug discovery tools. These aren't just one-off deals. They signal a shift toward platform-based approaches over pure therapeutic assets. Other disclosed rounds include Helical, Sable Bio, Ternary Therapeutics, Generare, Nuclera, and Umlaut.bio. All of them are building tools to make drug development earlier, more data-rich, and more experimentally grounded. All told, these reports point to over $70 million in 2026 funding across comparable biotech, bio-IT, AI drug discovery, and pharma infrastructure companies. ### Where ALP Bio Fits In ALP Bio sits in a specific niche: early risk reduction for biologics and antibody development. They're not focused on downstream clinical execution or broad AI discovery tooling. Instead, they're zeroing in on that critical window before clinical trials, when you can still course-correct without burning through your budget. Founded in 2025, the company is still young. But their approach of combining wet-lab immune biology with scalable computational design could be a game-changer. It moves developers from late-stage failure toward earlier, more actionable immunogenicity intelligence. The platform builds on human tonsil organoid technology, which models relevant immune activity in a dish. By integrating experimental readouts with AI, ALP Bio aims to give drug developers a clearer picture of risk before they commit to expensive clinical programs. ### What's Next for ALP Bio With this funding, the company plans to scale both the experimental and computational sides of their platform. They're also looking to partner with teams who want to make antibody development more predictable from the start. For an industry that has long accepted late-stage surprises as normal, that's a pretty compelling pitch.